The new drug for Relapsing Multiple Sclerosis (RMS), also approved for Primary Progressive Multiple Sclerosis (PPMS), is Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq). This drug was approved by the U.S. Food and Drug Administration (FDA) on September 13, 2024.
This information comes directly from an announcement by Genentech, a member of the Roche Group.
